Applied Genetics Inc. was founded focus on applications of DNA repair technology. Discoveries were just unfolding in this advancing field, particularly in understanding the power of repair to counteract solar UV and cancer chemotherapy. In 1998 the name was changed to AGI Dermatics to emphasize the company's focus on skin.The first patents on purification and delivery of DNA repair enzymes to skin were filed by AGI in 1988. The first clinical testing of purified DNA repair enzymes in humans was begun by AGI in 1993. The lead drug to prevent skin cancer is now in Phase III testing. As a private company, the emphasis on self-sufficiency led AGI to transform its proprietary liposome technology into active cosmetic ingredients that were launched in 1994. Prestige cosmetics containing AGI liposomes are now sold around the world. AGI applied its DNA repair technology to cancer diagnostics and filed the first patent in 1992 on methods to predict patient response from DNA repair ability. Clinical testing in brain cancer published in 1995 demonstrated its predictive value. Trials in breast and skin cancer are extending the technology.
